Evidence map›Paper›PMID 41821178›Full record

ReviewCancer biology & medicine2026

Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives.

Dayong Hou, Xiangpeng Li, Niyuan Zhang, Xingyan Fu, Hao Wang

Abstract readReview
In one paragraph

Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dayong Hou *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
Xiangpeng Li *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
Niyuan Zhang *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
Xingyan FuDepartment of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Hao WangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.ORCID 0000-0002-1961-0787

Funding

China National Postdoctoral Program for Innovative Talents BX20250301China Postdoctoral Science Foundation 2024M760683Harbin Medical University Cancer Hospital Haiyan Foundation JJYQ2024-03Heilongjiang Provincial Natural Science Foundation of China PL2024H159Hong Kong Scholar Project XJ2024052Ministry of Human Resources and Social Security National Foreign Expert Project D20250128National Key R&D Program of China 2022YFA1205701National Natural Science Foundation of China 52503171National Natural Science Foundation of China 82302266National Natural Science Foundation of China 82572288
6 · The paper itself

Abstract

Tumor theranostics, which integrates accurate diagnosis and precise therapy, has emerged as a pivotal approach in modern oncology for improving treatment efficacy and reducing off-target toxicity. Click chemistry, which is characterized by high efficiency, selectivity, biocompatibility, and modularity, has become an indispensable tool for constructing versatile theranostic systems. This review systematically summarizes the recent progress in click chemistry-based tumor theranostic systems, starting with an overview of core click reactions and the unique features in biomedical applications. We then focus on the application of click chemistry within a diagnosis-therapy-theranostics framework to three key aspects of tumor theranostics: (i) tumor diagnosis (molecular imaging probes and circulating tumor cell detection); (ii) tumor therapy (chemotherapy, phototherapy, immunotherapy, and gene therapy); and (iii) integrated theranostics (multimodal imaging-guided combinatorial therapy). Furthermore, the current challenges, such as the biocompatibility of catalysts and

Indexed as

Click ChemistryNeoplasmsTheranostic NanomedicineAnimalsHumansPrecision MedicineClick chemistryclinical translationmolecular imagingmultimodal integrationprecision therapytumor theranostics

Identifiers

PMID41821178
PMCPMC13115431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.